Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Verily
US FDA commissioner tells J.P. Morgan conference that the agency, industry, and the entire healthcare system need to change ‘at the same time’ in order for clinical trials to improve.
Japan-UK firm is looking to build on a combination of internal and external assets to pursue a more independent business development path in Japan and beyond, in parallel with ongoing discovery and development collaborations.
During Q3, biopharmas brought in an aggregate $18.1bn in financing and device company fundraising totaled $5.1bn; while in vitro diagnostic firms and research tools players raised $771m.
The idea seems to stem from thinking that human interaction is the best way to combat rumors and false statements.
- Implantable Devices
- Monitoring Equipment & Devices
In Vitro Diagnostics
- Glucose Testing
- Nanotechnology, Chips, etc.
Drug Discovery Tools
- Other Names / Subsidiaries
- Alphabet Inc.
- Verily Life Sciences LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.